Af­ter ground­break­ing year for RSV ap­provals, GSK looks to mod­el pe­di­atric suc­cess for adult vac­cines

In vac­cine de­vel­op­ment, 2023 will be re­mem­bered for ma­jor strides in RSV with the first-ever ap­provals and now three dif­fer­ent op­tions. While that’s good news …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER